Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SAF Stops Use of Usual Anti-Malaria Drug (Singapore)

This article was originally published in PharmAsia News

Executive Summary

The death of a Singapore solider due to an allergic reaction to the anti-malaria drug Maloprim has caused that country's army to cease handing it out as its typical medication. Maloprim is no longer given to Singapore solders before training in regions laden with mosquitoes in Singapore or overseas. Since April 2006, two different drugs have been handed out instead. The soldier who died from the maloprim reaction--Muhammad Sufian Jamil--experienced blood poisoning and multiple-organ failure after taking numerous doses of Maloprim between December 2005 and January 2006. Since 1985, 20,000 to 30,000 soldiers have taken maloprim annually without fatalities. Sufian, however, had an unusual condition known as Dapsone hypersensitivity syndrome, which no one knew about. The condition can cause a severe allergic reaction to an ingredient in Maloprim called Dapsone. (Click here for more - May Require Free Registration
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel